25 related articles for article (PubMed ID: 17962373)
1. In vitro, in vivo and in silico metabolic profiling of α-pyrrolidinopentiothiophenone, a novel thiophene stimulant.
Swortwood MJ; Carlier J; Ellefsen KN; Wohlfarth A; Diao X; Concheiro-Guisan M; Kronstrand R; Huestis MA
Bioanalysis; 2016; 8(1):65-82. PubMed ID: 26648097
[TBL] [Abstract][Full Text] [Related]
2. Identification of cytochrome P450 enzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-3-ethoxypropanamine and N-(1-phenylcyclohexyl)-3-methoxypropanamine.
Sauer C; Peters FT; Schwaninger AE; Meyer MR; Maurer HH
Chem Res Toxicol; 2008 Oct; 21(10):1949-55. PubMed ID: 18778087
[TBL] [Abstract][Full Text] [Related]
3. Identification of cytochrome p450 enzymes involved in the metabolism of 4'-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes.
Springer D; Paul LD; Staack RF; Kraemer T; Maurer HH
Drug Metab Dispos; 2003 Aug; 31(8):979-82. PubMed ID: 12867484
[TBL] [Abstract][Full Text] [Related]
4. Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 4'-hydroxymethyl-alpha-pyrrolidinobutyrophenone.
Peters FT; Dragan CA; Wilde DR; Meyer MR; Zapp J; Bureik M; Maurer HH
Biochem Pharmacol; 2007 Aug; 74(3):511-20. PubMed ID: 17572388
[TBL] [Abstract][Full Text] [Related]
5. Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine.
Sauer C; Peters FT; Schwaninger AE; Meyer MR; Maurer HH
Biochem Pharmacol; 2009 Feb; 77(3):444-50. PubMed ID: 19022226
[TBL] [Abstract][Full Text] [Related]
6. Studies on the metabolism and toxicological detection of the new designer drug 4'-methyl-alpha-pyrrolidinobutyrophenone (MPBP) in rat urine using gas chromatography-mass spectrometry.
Peters FT; Meyer MR; Fritschi G; Maurer HH
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Sep; 824(1-2):81-91. PubMed ID: 16046201
[TBL] [Abstract][Full Text] [Related]
7. Identification of cytochrome P450 enzymes involved in the metabolism of the new designer drug 4'-methyl-alpha-pyrrolidinobutyrophenone.
Peters FT; Meyer MR; Theobald DS; Maurer HH
Drug Metab Dispos; 2008 Jan; 36(1):163-8. PubMed ID: 17962373
[TBL] [Abstract][Full Text] [Related]
8. Biotechnological synthesis of drug metabolites using human cytochrome P450 isozymes heterologously expressed in fission yeast.
Peters FT; Bureik M; Maurer HH
Bioanalysis; 2009 Jul; 1(4):821-30. PubMed ID: 21083140
[TBL] [Abstract][Full Text] [Related]
9. In vitro approaches to studying the metabolism of new psychoactive compounds.
Peters FT; Meyer MR
Drug Test Anal; 2011; 3(7-8):483-95. PubMed ID: 21671427
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of designer drugs of abuse: an updated review.
Meyer MR; Maurer HH
Curr Drug Metab; 2010 Jun; 11(5):468-82. PubMed ID: 20540700
[TBL] [Abstract][Full Text] [Related]
11. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis.
Maurer HH; Kraemer T; Springer D; Staack RF
Ther Drug Monit; 2004 Apr; 26(2):127-31. PubMed ID: 15228152
[TBL] [Abstract][Full Text] [Related]
12. [New designer drugs. Pharmacology, toxicology and metabolism].
Staack RF; Springer D; Theobald DS; Maurer HH
Med Monatsschr Pharm; 2004 Dec; 27(12):408-13. PubMed ID: 15646689
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
